You just read:

InCarda Therapeutics Announces Positive Clinical Data Supporting Development of Inhaled Flecainide for the Treatment of Symptomatic Acute Events of Paroxysmal Atrial Fibrillation (PAF)

News provided by

InCarda Therapeutics, Inc.

Jun 07, 2017, 09:00 ET